Skip to main content
Hit enter to search or ESC to close
Search
Close Search
Menu
About
Company Overview
Executive Team
Board of Directors
Partnering
Hepatocellular Carcinoma
Portfolio
Newsroom
Investors
Investor Overview
Press Releases
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
linkedin
Menu
Investor Overview
Press Releases
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Press Releases
All Press Releases
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
March 3, 2026
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
June 25, 2025
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
June 16, 2025
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
May 12, 2025
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
May 7, 2025
Hepion Pharmaceuticals Announces Reverse Stock Split
March 14, 2025
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
January 22, 2025
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
December 11, 2024
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group
December 5, 2024
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
December 2, 2024
1
2
3
…
15
›
Close Menu
About
Company Overview
Executive Team
Board of Directors
Partnering
Hepatocellular Carcinoma
Portfolio
Newsroom
Investors
Investor Overview
Press Releases
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
linkedin
